Obiettivo AIDS is one of the most serious pandemic diseases of the modern era. Although current therapies based on targeting key processes of the HIV replication cycle are potent and selective, several clinical failures are recorded due to the emergence of drug resistance. Hence, there is an urgent need for novel drugs and alternative therapeutic strategies.The objective of the THINPAD proposal is to discover and develop novel anti-HIV agents targeting the HIV nucleocapsid protein(NC), which is one of the most conserved sequence within HIV strains and is highly required for HIV replication, being therefore a primary target to overcome antiretroviral drug-resistance. The proposal originates from the successful FP6 TRIoH project and presents a multidisciplinary approach to develop anti-HIV drugs, ready for early clinical trials, that could be resistant to viral mutation since targeting a highly conserved sequence.The consortium consists of experts in the anti-HIV field which have an extensive expertise in targeting NC. Partner 1 has studied the NC dynamics and discovered small molecule NC modulators by in silico approaches. Partner 2 has developed biophysical methods to monitor the NC functions and the interaction with small molecules. Partner 3 developed a complete approach of biochemistry-, retrovirology- and microscopy-based techniques to monitor NC during HIV assembly, maturation and reverse transcription. Partner 4 is a SME founded by scientists who participated in the development of Raltegravir, which will have a leading role in the project together with Partner 5 (SME) by driving the discovery phase and pre-clinical investigation, favouring the translation of results into innovative applications for health.It is worth noting that the consortium already possesses small molecules endowed with low-micromolar inhibitory activity in cell against HIV and active against resistant strains. Notably, these molecules interact with the NC but not with the usual anti-HIV targets Campo scientifico medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistance Programma(i) FP7-HEALTH - Specific Programme "Cooperation": Health Argomento(i) HEALTH.2013.2.3.1-1 - Drugs and vaccines for infections that have developed or are at the risk of developing significant anti-microbial resistance Invito a presentare proposte FP7-HEALTH-2013-INNOVATION-2 Vedi altri progetti per questo bando Meccanismo di finanziamento CP-FP - Small or medium-scale focused research project Coordinatore UNIVERSITA DEGLI STUDI DI SIENA Contributo UE € 1 143 750,00 Indirizzo VIA BANCHI DI SOTTO 55 53100 Siena Italia Mostra sulla mappa Regione Centro (IT) Toscana Siena Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Maurizio Botta (Prof.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Partecipanti (4) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER Spagna Contributo UE € 722 750,00 Indirizzo CALLE ROSSELLO 149 PUERTA BJS 08036 Barcelona Mostra sulla mappa Regione Este Cataluña Barcelona Tipo di attività Other Contatto amministrativo Pastora Martinez Samper (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato UNIVERSITE DE STRASBOURG Francia Contributo UE € 964 500,00 Indirizzo RUE BLAISE PASCAL 4 67081 Strasbourg Mostra sulla mappa Regione Grand Est Alsace Bas-Rhin Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Sandrine Schott (Mrs.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato IRBM SPA Italia Contributo UE € 2 386 700,00 Indirizzo VIA PONTINA KM 30600 00040 Pomezia Rm Mostra sulla mappa Regione Centro (IT) Lazio Roma Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Micol Estrella (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Costo totale Nessun dato VIROSTATICS SRL Italia Contributo UE € 474 250,00 Indirizzo VIALE UMBERTO I 46 07100 SASSARI Mostra sulla mappa Regione Isole Sardegna Sassari Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Franco Lori (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato